Faeth Therapeutics, Inc.

NasdaqCM:FTH Stock Report

Market Cap: US$19.5m

Faeth Therapeutics Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

Anand Parikh

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureless than a year
CEO ownershipn/a
Management average tenure1yrs
Board average tenureless than a year

Recent management updates

Recent updates

Analysis Article • Nov 03

Is Sensei Biotherapeutics (NASDAQ:SNSE) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
Analysis Article • Jul 02

We Think Sensei Biotherapeutics (NASDAQ:SNSE) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Analysis Article • Mar 14

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Aug 14

We're Hopeful That Sensei Biotherapeutics (NASDAQ:SNSE) Will Use Its Cash Wisely

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Aug 09

Sensei Biotherapeutics GAAP EPS of -$0.34 beats by $0.06

Sensei Biotherapeutics press release (NASDAQ:SNSE): Q2 GAAP EPS of -$0.34 beats by $0.06. Cash, cash equivalents and marketable securities were $123.7 million as of June 30, 2022, as compared to $147.6 million as of December 31, 2021. Sensei expects its current cash balance to fund operations into the first quarter of 2025.
Analysis Article • Apr 18

Here's Why We're Watching Sensei Biotherapeutics' (NASDAQ:SNSE) Cash Burn Situation

Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Analysis Article • Nov 16

Sensei Biotherapeutics (NASDAQ:SNSE) Is In A Good Position To Deliver On Growth Plans

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO

Anand Parikh (40 yo)

less than a year
Tenure

Mr. Anand Parikh, Esq., J.D., served as Chief Operating Officer and Director at Sensei Biotherapeutics, Inc. from February 17, 2026 and serves as its Chief Executive Officer and President since June 13, 20...

Leadership Team

NamePositionTenureCompensationOwnership
Josiah Craver
Senior VP of Finance1.8yrsUS$409.71k0%
$ 0
Christopher Gerry
General Counsel & Secretary3.9yrsUS$434.60k0.071%
$ 13.8k
Anand Parikh
CEO, COOless than a yearno datano data
Brian Stephenson
Chief Financial Officerno datano datano data
Lora Pike
Vice President of Investor Relations & Communicationsno datano datano data
1.0yrs
Average Tenure
45yo
Average Age

Experienced Management: FTH's management team is not considered experienced ( 1 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Anand Parikh
CEO, COOless than a yearno datano data
Robert Holmen
Independent Chairman9.4yrsUS$62.22k0.095%
$ 18.6k
Phillip Donenberg
Independent Directorless than a yearno data0%
$ 0
Richard Ulevitch
Member of Immuno-Oncology Advisory Board5.1yrsno datano data
Robert Schreiber
Member of Immuno-Oncology Advisory Boardno datano datano data
Sona Saira Ramasastry
Directorno datano datano data
Stephen Hahn
Directorno datano datano data
Alain Algazi
Member of Immuno-Oncology Advisory Boardno datano datano data
Daniel Sterman
Member of Immuno-Oncology Advisory Boardno datano datano data
Maura Gillison
Member of Immuno-Oncology Advisory Board5.1yrsno datano data
Sara Pai
Member of Immuno-Oncology Advisory Boardno datano datano data
0.3yrs
Average Tenure
63.5yo
Average Age

Experienced Board: FTH's board of directors are not considered experienced ( 0.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/17 12:01
End of Day Share Price 2026/06/16 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Faeth Therapeutics, Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Zhiqiang ShuBerenberg
Suranjit MukherjeeBTIG
Li Wang WatsekCantor Fitzgerald & Co.